Professor (Emeritus) Kohji Fukunaga
After graduating from the Graduate School of Pharmaceutical Sciences, Kumamoto University in 1980, Dr. Kohji Fukunaga was hired as an assistant at the Faculty of Medicine of the same university, and obtained a doctor of medicine in 1985. He has been studying as a postdoctoral fellow at Vanderbilt University in the United States since 1988. It was. In 1982, he discovered CaM kinase II (CaMKII), the role of CaMKII in spine dysplasia of mental retardation, regulation of dopamine D2 receptor function by fatty acid-binding protein (FABP), and Lewy's body disease by FABP. Many research results have been achieved, such as elucidation of the onset mechanism. In addition to his neuroscience, he has also contributed to drug discovery science, including the development of seeds for the treatment of Alzheimer's disease and Lewy body disease targeting CaMKII and FABP. In his academic activities, he served as the editorial chairman and director of the English journal, Journal of Pharmacological Sciences, for a long time, and made a great contribution to the Japanese Pharmacological Society. His enormous research results so far have been commercialized and he is now active in the drug discovery business.
The 8th Japanese Pharmacological Society Academic Encouragement Award, Kumamoto Medical Society Encouragement Award, Journal of Pharmacological Sciences Editor-in-Chief, Japanese Pharmacological Society Director, Japanese Pharmacological Society Director, Japanese Society of Brain Science Director, Japan NO Society Director, 47th President of the Japanese Pharmacological Society, etc.
Professor (Associate) Ichiro Kawahata
Dr. Ichiro Kawahata obtained a doctorate (science) from the Graduate School of Life Science and Engineering, Tokyo Institute of Technology in 2009, and was assigned to the Department of Pharmacology at the Graduate School of Pharmaceutical Sciences, Tohoku University in 2010 as an assistant professor, then appointed as a specially appointed assistant professor and an associate professor in 2020. He is working on the etiology of Parkinson's disease and development of therapeutic agents by the discovery of novel molecular mechanism that controls dopamine function, and exploration research of new drug discovery targets. In addition, he is also engaged in drug development research for dementia including Alzheimer's disease and Lewy body dementias. In addition to drug discovery research for Lewy body diseases, including Parkinson's disease, he has developed ultra-early diagnostic techniques that are essential for the prevention of individualized diseases. He is working toward the realization of a brain-healthy and long-lived society from each step of diagnosis, prevention and treatment.
36th Japanese Pharmacological Society Academic Encouragement Award, The 46th Japan Brain Science Society Encouragement Award, 17th Intelligent Cosmos Encouragement Award, APSBMS Outstanding Research Award, Japanese Pharmacological Society Academic Councilor, Frontiers in Neuroscience Guest Editor, etc.
Professor (Guest Associate) Hiroshi Yoshino (SHIRATORI Pharmaceutical Co., Ltd.)
Dr. Hiroshi Yoshino is participating in the Advanced Brain Drug Discovery Course from Shiratori Pharmaceutical Co., Ltd. As a member of Shiratori Pharmaceutical Co., Ltd., a world leader in organic synthesis and structural optimization of low-molecular-weight compounds, he is a leader in the development of cutting-edge brain function evaluation systems and seeds for psychiatric and neurodegenerative diseases. In this course, we will participate in therapeutic agents and diagnostic technologies that overcome dementia and intractable psychiatric disorders.